Bacterial Keratitis Medication
- Author: Fernando H Murillo-Lopez, MD; Chief Editor: Hampton Roy, Sr, MD more...
Topical antibiotics constitute the mainstay of treatment in cases of bacterial keratitis, with subconjunctival antibiotics used only under unusual circumstances, and systemic antibiotics used only in cases of perforation or specific organisms (eg, N gonorrhoeae). The use of topical corticosteroids remains controversial; however, when they are used, strict guidelines and close follow-up care are mandatory to ensure the best ultimate outcome of these patients.
Aminoglycosides have a broad range of bactericidal activity against many bacterial species, particularly gram-negative rods. They have a selective affinity to bacterial 30S and 50S ribosomal subunits to produce a nonfunctional 70S initiation complex that results in inhibition of bacterial cell protein synthesis. Unlike other antibiotics that impair protein synthesis, they are bactericidal. Their clinical activity is limited severely in anaerobic conditions. They have a low therapeutic/toxic ratio.
Cephalosporins have a broad spectrum of activity, including effective action against Haemophilus species. They contain a beta-lactam ring similar to penicillins, and a dihydrothiazine ring that makes them resistant to the action of penicillinases produced by staphylococci. They inhibit the third and final stage of bacterial cell wall formation by preferentially binding to one or more penicillin-binding proteins that are in the cytoplasmic membrane beneath the cell walls of susceptible bacteria. They are well tolerated topically.
Chloramphenicol usually is reserved for specific infections such as those associated with H influenzae. Its use has been limited by toxicity, including a dose-dependent bone marrow depression.
Macrolides are bacteriostatic agents (eg, erythromycin, tetracycline) that can suppress the growth of susceptible gram-positive cocci. This class of drugs works by inhibition of bacterial protein synthesis.
Glycopeptides have activity against gram-positive bacteria, and methicillin and penicillin-resistant staphylococci. They inhibit the biosynthesis of peptidoglycan polymers during the second stage of bacterial cell wall formation, at a different site of action from that of the beta-lactam antibiotics. They also have an excellent activity against a variety of gram-positive bacilli.
Sulfonamides have a structure similar to para -aminobenzoic acid (PABA), a precursor required by bacteria for folic acid synthesis. They competitively inhibit the synthesis of dihydropteroic acid, the immediate precursor of dihydrofolic acid from PABA pteridine. This inhibition does not affect mammalian cells because they lack the ability to synthesize folic acid and require preformed folic acid. They are active against gram-positive and gram-negative bacteria, and they are the preferred drugs against Nocardia keratitis.
Fluoroquinolones variably inhibit the action of bacterial DNA gyrase an enzyme essential for bacterial DNA synthesis. They have activity against most aerobic gram-negative bacteria and some gram-positive bacteria. Concern has been generated regarding the emerging resistance to fluoroquinolones among staphylococci. Emerging resistance to these antimicrobials has been reported in nonocular and ocular isolates. A study by Haas et al has revealed that among patients with ocular bacterial pathogens, resistance to 1 or more antibiotics is prevalent. They have limited efficacy against streptococci, enterococci, non-aeruginosa Pseudomonas, and anaerobes. Two multicenter trials compared the efficacy of ciprofloxacin 0.3% and ofloxacin 0.3% solution versus fortified cefazolin and tobramycin showing favorable efficacy for a single agent fluoroquinolone therapy.
They also have a record for low toxicity, good ocular surface penetration, and prolonged tear film penetration. Monotherapy for bacterial keratitis using these classes of antibiotics has been proved to be effective in large clinical trials. However, emerging resistance to the fluoroquinolones is now being reported in nonocular and ocular isolates. One randomized trial of 500 patients with bacterial corneal ulcer who received the fluoroquinolone moxifloxacin found a higher resistance to the agent was associated with worse clinical outcomes. Results show a rate of 1 line of vision loss per 32-fold increase in minimum inhibitory concentration.
Interferes with bacterial protein synthesis by binding to 30S and 50S ribosomal subunits, which results in a defective bacterial cell membrane. Add 2 mL of parenteral tobramycin (40 mg/cc) to 5 mL commercial 0.3% tobramycin solution. Refrigerate (expires in 7 d)
When mycobacteria are suspected. Irreversibly binds to 30S subunit of bacterial ribosomes; blocks recognition step in protein synthesis; causes growth inhibition.
Fortified cefazolin 50 mg/mL (Ancef, Kefzol, Zolicef)
First-generation cephalosporin with excellent gram-positive but narrow gram-negative activity. To prepare for topical use, dilute 500 mg parenteral cefazolin powder in sterile water to form 10 mL solution. Refrigerate (preparation expires in 7 d).
Third-generation cephalosporin has slightly less activity against gram-positive pathogens but more activity against gram-negative bacteria compared to a first-generation cephalosporin. To prepare, add 1 g parenteral ceftazidime powder to 9.2 cc of artificial tears. Add 5 cc of dilution to 5 cc of artificial tears, and shake well.
Acts by inhibiting bacterial protein synthesis. Binds reversibly to the 50S subunit of bacterial 70S ribosome and prevents attachment of the amino acid-containing end of the aminoacyl-tran to acceptor site on ribosome. Active in vitro against a wide variety of bacteria, including gram-positive, gram-negative, aerobic, and anaerobic organisms.
Ophthalmic ointment applied hs can be used in combination with a fluoroquinolone to improve coverage against streptococci and other gram-positive bacteria when dealing with small ulcers and outpatient treatment.
To prepare for topical administration, dilute 500 mg of parenteral vancomycin powder in 10 mL sterile water, artificial tears, or normal saline (0.9%). Refrigerate (preparation expires in 4 d). The 25 mg/mL concentration appears to be just as effective as the 50 mg/mL concentration but is much better tolerated by patients.
Laboratory diagnosis of Nocardia keratitis. Exerts bacteriostatic action by competitive antagonism of PABA, an essential component of folic acid synthesis.
Fluoroquinolone with activity against pseudomonads, streptococci, MRSA, S epidermidis, and most gram-negative organisms, but no activity against anaerobes. Inhibits bacterial DNA synthesis, and consequently growth.
A pyridine carboxylic acid derivative with broad-spectrum bactericidal effect.
Quinolone that has antimicrobial activity based on ability to inhibit bacterial DNA gyrase and topoisomerases, which are required for replication, transcription, and translation of genetic material. Quinolones have broad activity against gram-positive and gram-negative aerobic organisms. Differences in chemical structure between quinolones have resulted in altered levels of activity against different bacteria. Altered chemistry in quinolones result in toxicity differences.
Anti-inflammatory agents that may impair host defenses and enhance microbial proliferation, but can reduce host inflammatory response that contributes to conjunctival or corneal scarring. Should not be used until specific antimicrobial therapy has controlled microbial proliferation, and clear clinical improvement is evident. Judicious corticosteroid use entails dosage adjustment according to severity of ocular inflammation and occurrence of side effects. Discontinuation should be gradual to minimize rebound of inflammation.
Decreases inflammation by suppressing migration of polymorphonuclear leukocytes and reversing increased capillary permeability.
As the keratitis is controlled with antimicrobials, increase corticosteroids and decrease antibiotics.
Hall BJ, Jones L. Contact Lens Cases: The Missing Link in Contact Lens Safety?. Eye Contact Lens. 2010 Jan 19. [Medline].
Khan YA, Kashiwabuchi RT, Martins SA, Castro-Combs JM, Kalyani S, Stanley P. Riboflavin and ultraviolet light a therapy as an adjuvant treatment for medically refractive acanthamoeba keratitis report of 3 cases. Ophthalmology. 2011 Feb. 118(2):324-31. [Medline].
Haas W, Pillar CM, Torres M, Morris TW, Sahm DF. Monitoring Antibiotic Resistance in Ocular Microorganisms: Results From the Antibiotic Resistance Monitoring in Ocular MicRorganisms (ARMOR) 2009 Surveillance Study. Am J Ophthalmol. 2011 Oct. 152(4):567-574.e3. [Medline].
Lalitha P, Srinivasan M, Manikandan P, Bharathi MJ, Rajaraman R, Ravindran M, et al. Relationship of In Vitro Susceptibility to Moxifloxacin and In Vivo Clinical Outcome in Bacterial Keratitis. Clin Infect Dis. 2012 Mar 23. [Medline].
Bower KS, Kowalski RP, Gordon YJ. Fluoroquinolones in the treatment of bacterial keratitis. Am J Ophthalmol. 1996 Jun. 121(6):712-5. [Medline].
Caballero AR, Marquart ME, O'Callaghan RJ, Thibodeaux BA, Johnston KH, Dajcs JJ. Effectiveness of fluoroquinolones against Mycobacterium abscessus in vivo. Curr Eye Res. 2006 Jan. 31(1):23-9. [Medline].
Genvert GI, Cohen EJ, Donnenfeld ED. Erythema multiforme after use of topical sulfacetamide. Am J Ophthalmol. 1985 Apr 15. 99(4):465-8. [Medline].
Goldstein MH, Kowalski RP, Gordon YJ. Emerging fluoroquinolone resistance in bacterial keratitis: a 5-year review. Ophthalmology. 1999 Jul. 106(7):1313-8. [Medline].
Hirst LW, Harrison GK, Merz WG. Nocardia asteroides keratitis. Br J Ophthalmol. 1979 Jun. 63(6):449-54. [Medline].
Hirst LW, Smiddy WE, Stark WJ. Corneal perforations. Changing methods of treatment, 1960--1980. Ophthalmology. 1982 Jun. 89(6):630-5. [Medline].
Hyndiuk RA, Eiferman RA, Caldwell DR. Comparison of ciprofloxacin ophthalmic solution 0.3% to fortified tobramycin-cefazolin in treating bacterial corneal ulcers. Ciprofloxacin Bacterial Keratitis Study Group. Ophthalmology. 1996 Nov. 103(11):1854-62; discussion 1862-3. [Medline].
Knapp A, Stern GA, Hood CI. Mycobacterium avium-intracellulare corneal ulcer. Cornea. 1987. 6(3):175-80. [Medline].
Leibowitz HM. Clinical evaluation of ciprofloxacin 0.3% ophthalmic solution for treatment of bacterial keratitis. Am J Ophthalmol. 1991 Oct. 112(4 Suppl):34S-47S. [Medline].
Moore MB, Newton C, Kaufman HE. Chronic keratitis caused by Mycobacterium gordonae. Am J Ophthalmol. 1986 Oct 15. 102(4):516-21. [Medline].
Newman PE, Goodman RA, Waring GO 3d. A cluster of cases of Mycobacterium chelonei keratitis associated with outpatient office procedures. Am J Ophthalmol. 1984 Mar. 97(3):344-8. [Medline].
Parmar P, Salman A, Kalavathy CM. Comparison of topical gatifloxacin 0.3% and ciprofloxacin 0.3% for the treatment of bacterial keratitis. Am J Ophthalmol. 2006 Feb. 141(2):282-286. [Medline].
Pate JC, Jones DB, Wilhelmus KR. Prevalence and spectrum of bacterial co-infection during fungal keratitis. Br J Ophthalmol. 2006 Mar. 90(3):289-92. [Medline].
Poggio EC, Glynn RJ, Schein OD. The incidence of ulcerative keratitis among users of daily-wear and extended-wear soft contact lenses. N Engl J Med. 1989 Sep 21. 321(12):779-83. [Medline].
Schein OD, Glynn RJ, Poggio EC. The relative risk of ulcerative keratitis among users of daily-wear and extended-wear soft contact lenses. A case-control study. Microbial Keratitis Study Group. N Engl J Med. 1989 Sep 21. 321(12):773-8. [Medline].
Schlech BA, Alfonso E. Overview of the potency of moxifloxacin ophthalmic solution 0.5% (VIGAMOX). Surv Ophthalmol. 2005 Nov. 50 Suppl 1:S7-15. [Medline].
Stern GA, Buttross M. Use of corticosteroids in combination with antimicrobial drugs in the treatment of infectious corneal disease. Ophthalmology. 1991 Jun. 98(6):847-53. [Medline].
Stern GA, Schemmer GB, Farber RD. Effect of topical antibiotic solutions on corneal epithelial wound healing. Arch Ophthalmol. 1983 Apr. 101(4):644-7. [Medline].
Varma R, eds. Cornea/external diseases. Essentials of Eye Care: The Johns Hopkins Wilmer Handbook. Lippincott Williams & Wilkins. 1997:152-203.